Catalogue

Choose your language
Phones:
E-mail
hello@peptideseuro.com
We are on social networks
Go to contacts
0 0
Emerging

SS-31

Elamipretide (Mitochondria-Targeted Tetrapeptide)

SS-31 (elamipretide) is a synthetic tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it interacts with cardiolipin — a phospholipid essential for electron transport chain function. It is the most advanced mitochondrial-targeted peptide in clinical development, with published data from multiple Phase 2 and Phase 3 trials. Researchers study SS-31 because it addresses mitochondrial dysfunction at the structural level, not just the signaling level.

Aliases: Elamipretide, MTP-131, Bendavia

Research score
8/10

Mechanism

SS-31 (D-Arg-Dmt-Lys-Phe-NH2, also known as elamipretide/MTP-131/Bendavia) is a synthetic tetrapeptide that concentrates >1,000-fold in mitochondria due to electrostatic attraction between its positively charged arginine/lysine residues and negatively charged cardiolipin in the inner mitochondrial membrane (IMM). It stabilizes cardiolipin-dependent cristae structure, enhances electron transport chain (ETC) efficiency (particularly Complex III and IV), improves cytochrome c electron-carrying activity while reducing its peroxidase activity, scavenges reactive oxygen species, increases ATP production, and inhibits mitochondrial permeability transition pore (mPTP) opening. This prevents calcium overload and cytochrome c release (anti-apoptotic).

Evidence note

Emerging — Active clinical trials (Barth syndrome Phase 2/3, heart failure, kidney disease). Published in top journals (PNAS, Nature, eLife). Mechanism is well-characterized. Not yet FDA-approved but multiple clinical programs running. More human data than most peptides on this list (excluding approved ones).

Reference data

Molecular formula
C32H49N7O5
Sequence
D-Arg-Dmt-Lys-Phe-NH2

Studies

  • SS-31 and mitochondrial dysfunction

    Restored mitochondrial function and reduced oxidative stress in aged cardiac tissue.

    Open source · PMID 19064528

  • Elamipretide in heart failure

    Improved cardiac function in heart failure patients in Phase II clinical trials.

    Open source · PMID 26675167

  • Mitochondrial protein interaction landscape of SS-31 (PNAS)

    SS-31 primarily interacts with cardiolipin in the inner mitochondrial membrane; comprehensive interaction map reveals direct ETC stabilization.

    Open source · PMID 32817602

FAQ

How does it differ from MOTS-c?

Both target mitochondria but through different mechanisms. SS-31 stabilizes the electron transport chain directly, while MOTS-c activates AMPK and metabolic pathways.

Is SS-31 in clinical trials?

Yes. As elamipretide, it is in clinical trials for Barth syndrome and other mitochondrial diseases. It has FDA Rare Pediatric Disease and Breakthrough Therapy designations.

Why do some users experience initial fatigue with SS-31?

The initial fatigue/malaise effect is well-documented in the community and typically lasts 1-2 weeks before resolving. It may relate to mitochondrial remodeling as dysfunctional mitochondria are cleared. Community recommends methyl donor supplementation (B12, betaine, glycine) and starting at lower doses (2mg/day).

For research and educational use only. This content is not medical advice.